Demographic and clinical characteristics for ICI-treated patients
| Characteristic | Retrospective MCC ICI-treated patients (N=128) | Prospective MCC ICI-treated patients (N=49) | ||||||
| All | Deeply learned score | P values | All | Deeply learned score | P values | |||
| High (N=43) | Low (N=85) | High (N=31) | Low (N=18) | |||||
| Age (years) | 0.099 | 0.20 | ||||||
| Mean±SD | 65.48±13.24 | 67.35±13.71 | 64.54±12.80 | 66.8±10.04 | 64.77±8.87 | 70.28±10.70 | ||
| BMI | 0.43 | 0.48 | ||||||
| Mean±SD | 26.14±5.08 | 25.60±4.79 | 26.42±5.17 | 26.06±5.02 | 26.05±5.46 | 26.08±4.00 | ||
| Sex, No (%) | 0.38 | 0.56 | ||||||
| Male | 81 (63.28) | 24 (55.81) | 57 (67.06) | 25 (51.02) | 17 (54.84) | 8 (44.44) | ||
| Female | 47 (36.72) | 19 (44.19) | 28 (32.94) | 24 (48.98) | 14 (43.75) | 10 (55.56) | ||
| TNM stage | 0.63 | 0.39 | ||||||
| III | 25 (19.53) | 11 (25.58) | 14 (16.47) | 6 (12.24) | 5 (16.13) | 1 (5.56) | ||
| IV | 103 (80.47) | 32 (74.42) | 71 (83.53) | 43 (87.76) | 26 (83.87) | 17 (94.44) | ||
| Histology (baseline), No (%) | 0.096 | 0.23 | ||||||
| ADC | 80 (62.50) | 23 (53.49) | 57 (67.06) | 28 (57.14) | 20 (64.52) | 8 (44.44) | ||
| SCC | 48 (347.50) | 20 (46.51) | 28 (32.94) | 21 (42.86) | 11 (35.48) | 10 (55.56) | ||
| EGFR, No (%) | 1.00 | 1.00 | ||||||
| Mutation | 8 (6.25) | 2 (4.65) | 6 (7.06) | 2 (4.08) | 2 (6.45) | 0 | ||
| Wild | 85 (66.41) | 28 (65.12) | 57 (67.06) | 37 (75.51) | 23 (74.19) | 14 (77.78) | ||
| ALK, No (%) | 1.00 | NaN | ||||||
| Mutation | 2 (1.56) | 0 | 2 (2.35) | 0 | 0 | 0 | ||
| Wild | 89 (69.53) | 27 (62.79) | 62 (72.94) | 39 (79.59) | 24 (77.42) | 15 (83.33) | ||
| ROS1, No (%) | NaN | NaN | ||||||
| Mutation | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Wild | 35 (27.34) | 7 (16.28) | 28 (32.94) | 33 (67.35) | 20 (64.52) | 13 (72.22) | ||
| Smoke, No (%) | 0.78 | 0.74 | ||||||
| Never | 49 (38.28) | 18 (41.86) | 31 (36.47) | 14 (28.57) | 10 (32.26) | 4 (22.22) | ||
| Former | 79 (61.72) | 25 (58.14) | 54 (63.53) | 35 (71.43) | 21 (67.74) | 14 (77.78) | ||
| ECOG scale, No (%) | 0.43 | 0.49 | ||||||
| 0 | 29 (22.66) | 7 (16.28) | 22 (25.88) | 10 (16.33) | 5 (16.13) | 5 (27.78) | ||
| 1 | 91 (71.09) | 34 (79.07) | 57 (67.06) | 38 (81.63) | 25 (80.65) | 13 (42.22) | ||
| ≥2 | 8 (6.25) | 2 (4.65) | 6 (7.06) | 1 (2.04) | 1 (323) | 0 (0) | ||
| SUVmax | 0.014* | 0.15 | ||||||
| Mean±SD | 11.82±6.98 | 13.44±5.83 | 11.00±7.32 | 14.59±9.53 | 14.49±6.37 | 14.77±13.13 | ||
| Clinical benefit, No (%) | <0.001* | 0.005* | ||||||
| DCB | 69 (53.91) | 34 (79.07) | 35 (41.18) | 32 (65.31) | 25 (80.65) | 7 (38.89) | ||
| NDB | 59 (46.09) | 9 (20.93) | 50 (58.82) | 17 (34.69) | 6 (19.35) | 11 (61.11) | ||
| Progression-free survival | <0.001* | 0.015* | ||||||
| Median (95% CI) | 7.43 (6.39 to 8.47) | 15.80 (9.49 to 22.11) | 5.50 (2.87 to 8.13) | 10.50 (6.36 to 14.64) | 14.33 (8.57 to 20.10) | 5.00 (2.84 to 7.16) | ||
| Overall survival | 0.021* | <0.001* | ||||||
| Median (95% CI) | 21.77 (13.50 to 30.03) | 27.60 (NR) | 19.77 (13.82 to 25.72) | 17.00 (NR) | NR | 11.23 (6.69 to 15.78) | ||
| Deep learning score | <0.001* | <0.001* | ||||||
| Median (IQR) | 0.48 (0.01–0.93) | 0.63 (0.60–071) | 0.42 (0.32–0.48) | 0.55 (0.14–0.86) | 0.59 (0.56–064) | 0.34 (0.31–0.45) | ||
*p value<0.05. The comparison of age, BMI, and SUVmax between two groups was performed with Wilcoxon sign rank test, PFS and OS were compared with log-rank test, and the rest variables were compared with Fisher’s exact test.
ADC, adenocarcinoma; ALK, anaplastic lymphoma kinase; BMI, body mass index; DCB, durable clinical benefit; ECOG, Eastern Cooperative Oncology Group Performance Status; EGFR, epidermal growth factor receptor; ICI, immune checkpoint inhibitor; MCC, H Lee Moffitt Cancer Center and Research Institute; NDB, non-durable benefit; NR, not reached; SCC, squamous cell carcinoma; TNM, tumor, node, metastases.